We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks

Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks

Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks

Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ferrer has announced that it has licensed commercialization rights for Ozenoxacin one per cent cream in the United States of America, Puerto Rico and the U.S. Virgin Islands to Medimetriks Pharmaceuticals Inc.

Under the terms of the agreement Ferrer will be eligible to receive development milestones and revenues from sales in the Medimetriks territory.

In 2013 Ferrer successfully completed a first phase III clinical trial in adult and paediatric patients with impetigo. This involved Ozenoxacin formulated as a topical treatment for dermatological infectious conditions.

The study demonstrated the superiority of Ozenoxacin one per cent cream, applied topically twice daily for five days, versus a placebo on both the clinical and bacteriological endpoints by end of therapy visit.

In addition, Ozenoxacin demonstrated a superior bacteriological cure compared to placebo by the second visit (day three-four). The trial also demonstrated that Ozenoxacin is safe and very well tolerated in the adult and paediatric populations.

"We are proud to partner with Ferrer to maximize the commercialization of Ozenoxacin in the United States,” said Bradley Glassman, Medimetriks Chairman and Chief Executive. "We are committed to investing in the future of dermatology and ensuring that the dermatology community and its patients have new ways to treat unmet medical needs. Ozenoxacin is an example of our commitment. We expect our pace of investments in dermatology to increase."

“Impetigo due to bacterial skin infections remains a common problem, especially in infants and young children,” said Fernando Garcia Alonso, Chief Scientific Officer at Ferrer. “The emergence of treatment resistant bacterial pathogens underpins the need for alternative agents such as Ozenoxacin. The clinical studies performed by Ferrer with Ozenoxacin aim to provide infants and others with impetigo an alternative, safe and effective topical antibacterial treatment. In addition, Ozenoxacin could represent a topical treatment for a broad range of other infectious dermatological conditions.”

The product is available for licensing worldwide from Ferrer, except in China, Japan, Korea, Taiwan and the Medimetriks territory.